Newsroom
Albemarle Supports the Future of GLP-1 Therapies
GLP-1 therapies are transforming the way millions of people manage chronic conditions. First developed to treat type 2 diabetes, these medicines are now delivering breakthrough results in obesity care. But meeting this demand requires more than speed — it requires chemistry partners who can deliver precision and consistency at scale. That’s where Albemarle comes in.
ProductsOctober 27, 2025Albemarle Supports the Future of GLP-1 TherapiesGLP-1 therapies are revolutionizing care for diabetes and obesity, driving unprecedented demand and innovation. As pharmaceutical companies race to scale production and expand access, Albemarle stands ready as a trusted chemistry partner — delivering the precision, consistency and capacity needed to
ProductsOctober 22, 2025What’s the Difference Between Lithium Hydroxide and Lithium Carbonate?They may look like ordinary white powders, but lithium carbonate and lithium hydroxide have extraordinary roles. These compounds form the backbone of modern energy storage that powers everything from everyday electronics to advanced grid systems.
PeopleSeptember 19, 2025Ignacio Toro: Guiding Responsible Growth in ChileIgnacio Toro, Albemarle’s environmental manager in Chile, believes nature and development can coexist. His career — spanning government, nonprofits, and industry — focuses on sustainable, inclusive projects. At Albemarle, he leads a lithium extraction initiative using innovative, eco-friendly
PeopleAugust 13, 2025Jenny Nacu's Journey to Becoming a Lithium Leader and MentorJenny Nacu, a chemical engineer at Albemarle’s Kings Mountain facility, leads lithium hydroxide production with a focus on safety and performance. She mentors young engineers, encouraging growth through collaboration and resilience.
Press ReleasesNovember 05, 2025Albemarle Reports Third Quarter 2025 ResultsCHARLOTTE, N.C., Nov. 5, 2025 /PRNewswire/ -- Albemarle Corporation (NYSE: ALB), a global leader in providing essential elements for mobility, energy, connectivity and health, today announced its results for the third quarter ended September 30, 2025. Third Quarter 2025 and Recent Highlights (Unless- Press ReleasesOctober 27, 2025Albemarle Announces Quarterly Common Stock DividendCHARLOTTE, N.C. , Oct. 27, 2025 -- The Board of Directors of Albemarle Corp. (NYSE: ALB) announced today that it declared a quarterly common stock dividend of $0.405 per share. The dividend, which has an annualized rate of $1.62, is payable January 2, 2026, to shareholders of record at the close of
- Press ReleasesOctober 27, 2025Albemarle Announces Sale of a Controlling Stake in Ketjen to KPS Capital PartnersAlbemarle Separately Signs Agreement to Sell its 50% Stake in Eurecat Joint Venture to Axens SA Combined transactions strengthen Albemarle's financial flexibility and drive greater portfolio focus Albemarle expects to receive total pre-tax cash proceeds of approximately $660 million for the sale of
- Press ReleasesSeptember 25, 2025Albemarle Corporation to Release Third Quarter 2025 Earnings Results on Wednesday, November 5, 2025CHARLOTTE, N.C., Sept. 25, 2025 /PRNewswire/ -- Albemarle Corporation (NYSE: ALB), a global leader in providing essential elements for mobility, energy, connectivity and health, announced today that it will release its third quarter 2025 earnings after the NYSE closes on Wednesday, November 5, 2025
From Resources - Mine and Brine - To Market
Download our media fact sheet to learn the role Albemarle plays in the extraction, conversion and processing of lithium and bromine.
Press & Media Contact
For press & media inquiries, please contact our Media Relations team - for all other inquiries please go through the Contact Us page.